An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

References

• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021;386(7):640–654. doi: 10.1056/NEJMoa2116133.
   PubMed Web of Science ®Google Scholar
• Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148–157. doi: 10.1056/NEJMoa2301665.
   PubMed Web of Science ®Google Scholar
• Perales MA, Kuruvilla J, Snider JT, et al. The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial. Transplant Cell Ther. 2022;28(11):750.e1-750–e6. doi: 10.1016/j.jtct.2022.08.010.
   Google Scholar
• Kambhampati S, Saumoy M, Schneider Y, et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022;140(19):2024–2036. doi: 10.1182/blood.2022016747.
   PubMed Web of Science ®Google Scholar
• Tai T-A, Latimer NR, Benedict Á, et al. Prevalence of immature survival data for anti-cancer drugs presented to the national institute for health and care excellence and impact on decision making. Value Health. 2021;24(4):505–512. doi: 10.1016/j.jval.2020.10.016.
   PubMed Web of Science ®Google Scholar
• Borgert R. Improving outcomes and mitigating costs associated with CAR T-cell therapy. Am J Manag Care. 2021;27(13 Suppl):S253–s261. doi: 10.37765/ajmc.2021.88737.
   PubMed Web of Science ®Google Scholar
• Vadgama S, Mann J, Bashir Z, et al. Predicting survival for chimeric antigen receptor T-cell therapy: a validation of survival models using follow-up data from ZUMA-1. Value Health. 2022;25(6):1010–1017. doi: 10.1016/j.jval.2021.10.015.
   PubMed Web of Science ®Google Scholar
• NICE. Final appraisal document: axicabtagene ciloleucel for treating relapsed or refractor diffuse large B-cell lymphoma after first-line chemoimmunotherapy. 2023.
   Google Scholar
• Latimer NR, Abrams KR. NICE DSU Technical Support Document 16: adjusting survival time estimates in the presence of treatment switching. 2014.
   Google Scholar
• Gold MR. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
   Google Scholar
• Kersten MJ, Qiao Y, Shah R, et al. Quality-adjusted time without symptoms or toxicity: analysis of axicabtagene ciloleucel versus standard of care in patients with relapsed/refractory large B cell lymphoma. Transplant Cell Ther. 2023;29(5):335.e1–335-e8. doi: 10.1016/j.jtct.2023.01.008.
   Google Scholar
• Chen AJ, Zhang J, Agarwal A, et al. Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-cell lymphoma. Value Health. 2022;25(8):1344–1351. doi: 10.1016/j.jval.2022.02.007.
   PubMed Web of Science ®Google Scholar
• Kourelis T, Bansal R, Patel KK, et al. Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access. J Clin Oncol. 2022;40(16_suppl):e20021–e20021. doi: 10.1200/JCO.2022.40.16_suppl.e20021.
   Web of Science ®Google Scholar
• Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. J Clin Oncol Oncol Pract. 2022;18(12):800–807. doi: 10.1200/OP.22.00315.
   PubMedGoogle Scholar
• Shafrin J, Quddus S, Marin M, et al. A decade of health innovation: the impact of new medicines on patient health and the implications for NICE’s size of benefit multiplier. Value Health. 2023;26(10):1435–1439. doi: 10.1016/j.jval.2023.06.009.
   PubMed Web of Science ®Google Scholar
• Choe JH, Abdel-Azim H, Padula WV, et al. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open. 2022;5(12):e2245956. doi: 10.1001/jamanetworkopen.2022.45956.
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Kuruvilla J, Crump M, et al. Cost-effectiveness analysis of frontline polatuzumab-rituximab, cyclophosphamide, doxorubicin, and prednisone and/or second-line chimeric antigen receptor T-cell therapy versus standard of care for treatment of patients with intermediate- to high-risk diffuse large B-cell lymphoma. J Clin Oncol. 2023;41(8):1577–1589. doi: 10.1200/JCO.22.00478.
   PubMed Web of Science ®Google Scholar
• Tavakkoli M, Barta SK. 2024 Update: advances in the risk stratification and management of large B-cell lymphoma. Am J Hematol. 2023;98(11):1791–1805. doi: 10.1002/ajh.27075.
   PubMedGoogle Scholar
• Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245. doi: 10.1080/13696998.2018.1529674.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410–420. doi: 10.1177/0272989X06290495.
   PubMed Web of Science ®Google Scholar
• NICE. Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies [TA567]. Technology appraisal guidance. London: National Institute for Health and Care Excellence; 2019.
   Google Scholar
• RED BOOK. 2023. [cited 20021 Nov 1]. Available from: https://www.ibm.com/products/micromedex-red-book.
   Google Scholar
• Liu R, Oluwole OO, Diakite I, et al. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24(1):458–468. doi: 10.1080/13696998.2021.1901721.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Physician fee schedule 2023 [cited 2023 Mar 31]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched.
   Google Scholar
• Dasta JF, McLaughlin TP, Mody SH, et al. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33(6):1266–1271. doi: 10.1097/01.ccm.0000164543.14619.00.
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Smith PJ, Dembek CJ. Payer costs of autologous stem cell transplant: results from a U.S. claims data analysis. Blood. 2008;112(11):2373–2373. doi: 10.1182/blood.V112.11.2373.2373.
   Google Scholar
• Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10(7):366–374.
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin’s lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006;47(8):1535–1544. doi: 10.1080/10428190600573325.
   PubMed Web of Science ®Google Scholar
• Surveillance EaERP. Cancer stat facts: NHL - diffuse large B-cell lymphoma (DLBCL). 2021. [cited 2021 Nov 1]. Available from: https://seer.cancer.gov/statfacts/html/dlbcl.html.
   Google Scholar
• Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842–858. doi: 10.1056/NEJMra2027612.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquières H, Jais J-P, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073. doi: 10.1200/JCO.2013.51.5866.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011(1):498–505. doi: 10.1182/asheducation-2011.1.498.
   PubMed Web of Science ®Google Scholar